Long-acting analog insulin doesn't up AMI risk in T2DM

August 20, 2015
Long-acting analog insulin doesn't up AMI risk in T2DM

(HealthDay)—For patients with type 2 diabetes, the risk of acute myocardial infarction (AMI) is not significantly different for long-acting insulin analogs versus other basal insulin therapies, according to a study published online Aug. 17 in Diabetes, Obesity and Metabolism.

Bianca Kollhorst, from the Leibniz Institute for Prevention Research and Epidemiology in Bremen, Germany, and colleagues examined the risk of AMI in patients with mellitus in a . The risk of AMI was compared for patients treated with long-acting analogs versus other basal insulin therapy.

The researchers identified 21,501 new insulin users. Patients treated with premixed insulin were older than those treated with analog or human neutral protamine Hagedorn (NPH) insulin (mean age, 70.7 versus 64.1 and 61.6 years, respectively); they also had a higher number of comorbidities. There was no significant difference in the risk of AMI for those receiving NPH or analog insulin (hazard ratio, 0.94; 95 percent confidence interval, 0.74 to 1.19), but the risk was higher for premixed versus analog insulin (hazard ratio, 1.27; 95 percent confidence interval, 1.02 to 1.58). There was no increased risk for premixed insulin in propensity score-matched analysis.

"In contrast to a former database study, no difference was observed for the risk of AMI between long-acting analog and NPH insulin in this study," the authors write. "Neither long-acting analog insulin nor premix insulin appears to be associated with AMI in patients with type 2 diabetes."

Two authors are employed by Sanofi-Aventis, which funded the study.

Explore further: Gender-based differences in glycemic control in T2DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Gender-based differences in glycemic control in T2DM

May 26, 2015

(HealthDay)—For patients with type 2 diabetes, there are gender-based differences in glycemic control and hypoglycemia after insulin treatment, according to research published in the June issue of Diabetes, Obesity and ...

CVD risk similar for metformin + insulin or sulfonylureas

July 20, 2015

(HealthDay)—For patients with type 2 diabetes, the risk of myocardial infarction (MI) or stroke is similar for treatment with insulin or sulfonylureas in combination with metformin, according to a study published online ...

No increased cancer risk with glargine versus human insulin

August 6, 2013

(HealthDay)—There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study ...

Recommended for you

Many diabetes patients produce some insulin

June 22, 2017

Some insulin is still produced in almost half of patients that have had type 1 diabetes for more than ten years. The study conducted by researchers at Uppsala University in Sweden has now been published online by the medical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.